Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs

Transfusion

Volumn 44, Issue 1, 2004, Pages 25-29

  King, Karen E ^a   Shirey, R Sue ^a   Thoman, Sandra K ^a   Bensen Kennedy, Debra ^a   Tanz, Warren S ^a   Ness, Paul M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC REACTION; BLOOD; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEVER; HUMAN; LEUKOCYTE; REVIEW;

ERYTHROCYTE TRANSFUSION; FEVER; HUMANS; HYPERSENSITIVITY; INCIDENCE; LEUKAPHERESIS; RETROSPECTIVE STUDIES;

EID: 0842281750     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0041-1132.2004.00609.x     Document Type: Review

References (13)

1. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev 2001;15:69-83.
2. Heddle NM, Klama LN, Griffith L, et al. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993;33:794-7.
3. Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: what blood component should be given next? Vox Sang 1982;42:318-21.
4. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994;84:1703-21.
5. Dzik S, Aubuchon J, Jeffries L, et al. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 2000;14:34-52.
6. Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001;41:997-1000.
7. Shiba M, Tadokoro K, Sawanobori M, et al. Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets. Transfusion 1997;37:457-62.
8. Goodnough LT. The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion 2000;40:1522-7.
9. Reverberi R, Ferrari L, Gennari M, Menini C. Prevention of non-hemolytic transfusion reactions with leucocyte-poor blood: a prospective study. Haematologica 1989;74:283-8.
10. Tanz WS, King KE, Ness PM. Unexpected transfusion reaction rates associated with leukocyte-reduced red blood cells. Transfusion 2000;40:125S.
11. Thurer RL, Luban NL, AuBuchon JP, et al. Universal WBC reduction. Transfusion 2000;40:751-2.
12. Dzik WH, Anderson JK, O'Neill EM, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002;42:1114-22.
13. Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003;289:1941-9.